Literature DB >> 35237907

Multi-catalytic Sites Inhibition of Bcl2 Induces Expanding of Hydrophobic Groove: A New Avenue Towards Waldenström Macroglobulinemia Therapy.

Ghazi Elamin1, Aimen Aljoundi1, Mahmoud E S Soliman2.   

Abstract

B-cell lymphoma 2 (Bcl2) is a key protein regulator of apoptosis. The hydrophobic groove in Bcl2 is a unique structural feature to this class of enzymes and found to have a profound impact on protein overall structure, function, and dynamics. Dynamics of the hydrophobic groove is an essential determinant of the catalytic activity of Bcl2, an implicated protein in Waldenström macroglobulinemia (WM). The mobility of α3-α4 helices around the catalytic site of the protein remains crucial to its activity. The preferential binding mechanisms of the multi-catalytic sites of the Bcl2 enzyme have been a subject of debate in the literature. In addition to our previous report on the same protein, herein, we further investigate the preferential binding modes and the conformational implications of Venetoclax-JQ1 dual drug binding at both catalytic active sites of Bcl2. Structural analysis revealed asymmetric α3-α4 helices movement with the expansion of the distance between the α3 and α4 helix in Venetoclax-JQ1 dual inhibition by 15.2% and 26.3%, respectively when compared to JQ1 and Venetoclax individual drug inhibition-resulting in remarkable widening of hydrophobic groove. Moreso, a reciprocal enhanced binding effect was observed: Venetoclax increased the binding affinity of JQ1 by 11.5%, while the JQ1 fostered the binding affinity of Venetoclax by 16.3% compared with individual inhibition of each drug. This divergence has also resulted in higher protein stability, and prominent correlated motions were observed with the least fluctuations and multiple van der Waals interactions. Findings offer vital conformational dynamics and structural mechanisms of enzyme-single ligand and enzyme-dual ligand interactions, which could potentially shift the current therapeutic protocol of Waldenström macroglobulinemia.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Bcl2; Hydrophobic groove; JQ1; Venetoclax; Waldenström macroglobulinemia

Mesh:

Substances:

Year:  2022        PMID: 35237907     DOI: 10.1007/s10930-022-10046-9

Source DB:  PubMed          Journal:  Protein J        ISSN: 1572-3887            Impact factor:   2.371


  44 in total

Review 1.  Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

Authors:  Roger G Owen; Steven P Treon; Ayad Al-Katib; Rafael Fonseca; Philip R Greipp; Mary L McMaster; Enrica Morra; Gerassimos A Pangalis; Jesus F San Miguel; Andrew R Branagan; Meletios A Dimopoulos
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

Review 2.  Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.

Authors:  Christian Buske; Shalal Sadullah; Efstathios Kastritis; Alessandra Tedeschi; Ramón García-Sanz; Lukasz Bolkun; Xavier Leleu; Wolfgang Willenbacher; Roman Hájek; Monique C Minnema; Mei Cheng; Elizabeth Bilotti; Thorsten Graef; Meletios A Dimopoulos
Journal:  Lancet Haematol       Date:  2018-07       Impact factor: 18.959

3.  Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.

Authors:  Mathias J Rummel; Norbert Niederle; Georg Maschmeyer; G Andre Banat; Ulrich von Grünhagen; Christoph Losem; Dorothea Kofahl-Krause; Gerhard Heil; Manfred Welslau; Christina Balser; Ulrich Kaiser; Eckhart Weidmann; Heinz Dürk; Harald Ballo; Martina Stauch; Fritz Roller; Juergen Barth; Dieter Hoelzer; Axel Hinke; Wolfram Brugger
Journal:  Lancet       Date:  2013-02-20       Impact factor: 79.321

4.  Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis.

Authors:  Adam J Olszewski; Steven P Treon; Jorge J Castillo
Journal:  Oncologist       Date:  2016-07-29

5.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation.

Authors:  Y Tsujimoto; L R Finger; J Yunis; P C Nowell; C M Croce
Journal:  Science       Date:  1984-11-30       Impact factor: 47.728

6.  Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.

Authors:  Meletios Athanasios Dimopoulos; Athanasios Anagnostopoulos; Marie-Christine Kyrtsonis; Konstantinos Zervas; Constantinos Tsatalas; Garyfallia Kokkinis; Panagiotis Repoussis; Argyris Symeonidis; Souzana Delimpasi; Eirini Katodritou; Elina Vervessou; Evridiki Michali; Anastasia Pouli; Dimitra Gika; Amalia Vassou; Evangelos Terpos; Nikolaos Anagnostopoulos; Theophanis Economopoulos; Gerasimos Pangalis
Journal:  J Clin Oncol       Date:  2007-06-18       Impact factor: 44.544

Review 7.  Bcl-2 family proteins and cancer.

Authors:  K W Yip; J C Reed
Journal:  Oncogene       Date:  2008-10-27       Impact factor: 9.867

8.  Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

Authors:  Steven P Treon; Leukothea Ioakimidis; Jacob D Soumerai; Christopher J Patterson; Patricia Sheehy; Marybeth Nelson; Michael Willen; Jeffrey Matous; John Mattern; Jakow G Diener; George P Keogh; Thomas J Myers; Andy Boral; Ann Birner; Dixie L Esseltine; Irene M Ghobrial
Journal:  J Clin Oncol       Date:  2009-06-08       Impact factor: 44.544

Review 9.  How I treat Waldenström macroglobulinemia.

Authors:  Meletios A Dimopoulos; Efstathios Kastritis
Journal:  Blood       Date:  2019-12-05       Impact factor: 22.113

10.  Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition.

Authors:  Stephan J Matissek; Weiguo Han; Mona Karbalivand; Mohamed Sayed; Brendan M Reilly; Shayna Mallat; Shimaa M Ghazal; Manit Munshi; Guang Yang; Steven P Treon; Sarah R Walker; Sherine F Elsawa
Journal:  Epigenomics       Date:  2020-12-24       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.